PAA.AU · PharmAust Limited

-

Please sign in to comment on PAA.AU

1 Comment

Admin

4 years ago

PharmAust Limited is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.

From a valuation standpoint, the stock is 95.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.0.

PharmAust Limited's total revenue sank by 27.2% to $2M since the same quarter in the previous year.

Its net income has dropped by 71.7% to $-832K since the same quarter in the previous year.

Finally, its free cash flow grew by 56.5% to $-314K since the same quarter in the previous year.

Based on the above factors, PharmAust Limited gets an overall score of 2/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU000000PAA1
Sector	Healthcare
Industry	Biotechnology

Target Price	None
Market Cap	112M
PE Ratio	None
Beta	1.55
Dividend Yield	None

ABOUT

PharmAust Limited

PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.

PAA.AU · PharmAust Limited

-

PharmAust Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest PharmAust Limited using a moving average strategy